A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Stopped early · Phase 1

Conditions studied: BRAF V600 Colorectal Cancer

In brief

A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

Key facts

Study ID

NCT04294160

Run by

Novartis Pharmaceuticals

People needed

122

Starts

2020-07-22

Expected to finish

2024-09-25

Last updated by the study team

2025-12-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California LA Santa Monica Location — Los Angeles, California, United States
• Massachusetts General Hospital Massachusetts General Hospital — Boston, Massachusetts, United States
• Sarah Cannon Research Institute SC — Nashville, Tennessee, United States
• Uni Of TX MD Anderson Cancer Cntr — Houston, Texas, United States
• Novartis Investigative Site — Westmead, New South Wales, Australia
• Novartis Investigative Site — Brussels, Belgium
• Novartis Investigative Site — Leuven, Belgium
• Novartis Investigative Site — Toronto, Ontario, Canada
• Novartis Investigative Site — Dresden, Germany
• Novartis Investigative Site — Essen, Germany
• Novartis Investigative Site — Ulm, Germany
• Novartis Investigative Site — Tel Aviv, Israel
• Novartis Investigative Site — Zoetermeer, Netherlands
• Novartis Investigative Site — Singapore, Singapore
• Novartis Investigative Site — Barcelona, Catalonia, Spain
• Novartis Investigative Site — Valencia, Valencia, Spain
• Novartis Investigative Site — Madrid, Spain
• Novartis Investigative Site — Manchester, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.